Novartis AG (NVS)
Market Cap | 195.35B |
Revenue (ttm) | 49.94B |
Net Income (ttm) | 17.60B |
Shares Out | 2.00B |
EPS (ttm) | 8.58 |
PE Ratio | 11.10 |
Forward PE | 12.13 |
Dividend | $3.78 (3.87%) |
Ex-Dividend Date | Mar 7, 2024 |
Volume | 1,346,124 |
Open | 98.37 |
Previous Close | 97.86 |
Day's Range | 97.45 - 98.51 |
52-Week Range | 92.35 - 120.92 |
Beta | 0.51 |
Analysts | Hold |
Price Target | 121.25 (+24.32%) |
Earnings Date | Jan 31, 2025 |
About NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $121.25, which is an increase of 24.32% from the latest price.
News
US appeals court lifts pause on generic version of Novartis' Entresto
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary ...
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet...
Novartis loses emergency bid to block Entresto generic in US
A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug En...
Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Novartis AG (NYSE:NVS) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vo...
Novartis CEO: We need to get Europe to pay its fair share
Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite Bi...
Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination ...
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
Novartis experienced a strong bull run in 2024 but saw a 13% pullback post-Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 p...
AI, vaccine distrust, & the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.
Light Horse Therapeutics Enters Into Strategic Collaboration With Novartis
SAN DIEGO--(BUSINESS WIRE)--Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop poten...
Novartis gene therapy helps children with rare muscle disorder in study
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow.
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onase...
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis...
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying...
Novartis: Time To Increase
Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include hig...
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Basel, December 10, 2024 – Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the du...
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR) r...
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid...
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan...
Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast ca...
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecule...
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological diso...